Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether neoadjuvant intravesical Gemcitabine is enough active in patients with a solitary, low risk superficial bladder cancer.After diagnostic urethrocystoscopy or bladder sonography, all patients will receive intravesical gemcitabine once a week during 6 weeks. Two weeks after finishing antiblastic therapy, all patients will be submitted to a new cystoscopy, with TUR or cold biopsies of the site of the initial lesion.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00191711
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date February 2004
Completion date October 2005

See also
  Status Clinical Trial Phase
Completed NCT01687244 - Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Phase 2
Completed NCT02773849 - ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Phase 3
Recruiting NCT03379909 - Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer Phase 2
Completed NCT00782587 - Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer Phase 1
Recruiting NCT05084586 - Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation N/A
Recruiting NCT03121768 - A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) N/A
Completed NCT03091764 - Evaluation of a Patient-Reported Symptom Index for NMIBC
Completed NCT01939756 - Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms Phase 1/Phase 2
Completed NCT00595088 - Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Phase 2
Completed NCT02007005 - Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer Phase 1/Phase 2
Completed NCT01149174 - Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer Phase 3
Completed NCT00322699 - Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer Phase 1/Phase 2
Completed NCT00192049 - A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer Phase 2
Recruiting NCT04752722 - LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Phase 1/Phase 2
Recruiting NCT02106572 - Therapeutic Instillation of Mistletoe Phase 3
Completed NCT00734994 - Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer Phase 0